Compass Pathways Aktie - 5Y6

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

4,00

Gebot

3,96

Fragen

4,04

Volumen

700

4,00 Tagesbereich 4,00

2,00 52-Wochen-Bereich 7,60

Handelsende

4,04

Handelsbeginn

4,00

Letzte Trade

700

Letzter Handelszeitpunkt

08:17:15

Durchschnittliches Volumen (3 Mio.)

3.550

Finanzvolumen

VWAP

Compass Pathways announces second quarter 2024 financial results and business highlights

Compass Pathways announces second quarter 2024 financial results and business highlights Top-line COMP005 data for COMP360 phase 3 pivotal program...

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways appoints Lori Englebert as Chief Commercial Officer New executive appointment made ahead of pivotal study results, potential...

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights COMP360 phase 3 pivotal program in...

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic...

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective...

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery...

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors David...

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE...

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for...

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement Three-year research collaboration will investigate...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.24	6.3829787234	3.76	4.44	3.76	4888	4.08639636	DE
4	0.18	4.71204188482	3.82	4.5	3.6	3489	4.05286546	DE
12	1.32	49.2537313433	2.68	4.5	2	3550	3.4294528	DE
26	0.14	3.62694300518	3.86	5.05	2	3643	3.57086291	DE
52	-1.85	-31.6239316239	5.85	7.6	2	2928	4.33178907	DE
156	-4.6	-53.488372093	8.6	11.5	2	2524	5.61021788	DE
260	-4.6	-53.488372093	8.6	11.5	2	2524	5.61021788	DE

5Y6 - Frequently Asked Questions (FAQ)

What is the current Compass Pathways share price?

The current share price of Compass Pathways is 4,00 €

What is the 1 year trading range for Compass Pathways share price?

Compass Pathways has traded in the range of 2,00 € to 7,60 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
E3O1Nexoptic Technology Corp	0,0105 € (31,25%)	18k
NEJNine Energy Service Inc	1,198 € (30,79%)	177,91k
634Exploits Discovery Corp	0,035 € (29,63%)	50k
20MPMountain Valley MD Holdings Inc	0,0184 € (27,78%)	9,65k
UE22US Energy Corp	1,95 € (27,04%)	42,06k
WIG1Wige Media AG	0,013 € (-25,71%)	10k
UH7ATennant Minerals NL	0,003 € (-25,00%)	32,97k
FX8Celsius Resources Limited	0,003 € (-25,00%)	133,33k
C0MCCS Abwicklungs AG	0,086 € (-19,63%)	10,02k
7YGSyntheia Corp	0,0355 € (-17,44%)	150k
PF8European Lithium Limited	0,031 € (-6,63%)	974,93k
3CPXiaomi Corporation	6,03 € (1,62%)	769,56k
DRHDroneShield Limited	1,032 € (-7,19%)	627,73k
E3BEutelsat Communications	3,855 € (7,68%)	591,12k
24YBrainchip Holdings Ltd	0,1097 € (-6,00%)	477,83k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Compass Pathways Plc (5Y6)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

5Y6 Neueste Nachrichten

Compass Pathways announces second quarter 2024 financial results and business highlights

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

5Y6 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Compass Pathways Plc (5Y6) Börsenkurse

Compass Pathways Plc (5Y6)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

5Y6 Neueste Nachrichten

Compass Pathways announces second quarter 2024 financial results and business highlights

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

5Y6 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Anmelden

Werbung entfernen